PTO/SB/08a/b (08-03)
Approved for use through 07/31/2005. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paparwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid CMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	Divisi nal of 10/268,059 February 5, 2004	
INF	<b>ORMATI</b>	ON DISC	LOSURE	Filing Date		
STATEMENT BY APPLICANT (Use as many sheets as necessary)				First Named Inventor	David Edwards	
				Art Unit	N/A	
				Examiner Name	Not Yet Assigned	
Sheet	1	of	2	Attorney Docket Number	000166.0109-US03	

4

U.S. PATENT DOCUMENTS  Document Number Pages, Columns, Lines, Wh							
Examin nitials		Cite No.	Document Number  Number-Kind Code <sup>2</sup> ( # known)	Publication Date MM-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevan	
		AA_	⊎6-3,635,219-B1	01/1972	Altounyan et al.		
		AB	US-3,669,113-B1	06/1972	Altounyan et al.		
7		AC	US-3,795,244-B1	03/1974	Lax et al.		
		AD	US-3,837,341-B1	09/1974	Bell		
$\neg$		ΑE	US-3,888,253-B1	06/1975	Watt et al.		
. 1		AF	US-3,906,950	09/1975	Cocozza		
7		AG	US-4,013,075	03/1977	Cocozza		
		АН	US-4,069,228	01/1978	Valentini et al.		
		ΑI	US-4,069,819-B1	01/1978	Valentini et al.		
		AJ	US-4,105,027-B1	08/1978	Lundquist		
		AK	US-4,192,309	03/1980	Poulsen		
	Γ	AL	US-4,240,418	12/1980	Rosskamp et al.		
	П	АМ	US-4,860,740	08/1989	Kirk et al.		
	T	AN	US-4,889,114-B1	12/1989	Kladders		
	T	AO	US-4,995,285	02/1991	Valentini et al.		
,	Τ	AP	US-5,152,284-B1	10/1992	Valentini et al.		
	T	AQ	US-5,239,992-B1	08/1993	Bougamont et al.		
	1	AR	US-5,301,666-B1	04/1994	Lerk et al.		
	T	AS	US-5,349,947	09/1994	Newhouse et al.		
	Τ	AT	US-5,595,175-B1	01/1997	Malcher et al.		
	T	AU	US-5,647,349	07/1997	Ohki et al.		
	$\top$	ΑV	US-5,651,359	07/1997	Bougamont et al.		
	1	AW	US-5,673,686-B1	10/1997	Villax et al.		
		AX	US-5,685,294	11/1997	Gupte et al.		
	T	AY	US-5,727,546	03/1998	Clarke et al.		
			US-5,740,794	04/1998	Smith et al.		
	T		US-5,785,049	07/1998	Smith et al.		
			US-5,797,391	08/1998	Cook et al.		
		AC1	US-5,810,004	09/1998	Ohki et al.		
	T	AD1	US-5,860,419	01/1999	Davies et al.		
	T	AE1	US-5,896,855-B1	04/1999	Hobbs et al.		
	T	AF1	US-5,921,237	07/1999	Eisele et al.		
	I	AG1	US-6,089,228	07/2000	Smith et al.		
	$\Gamma$		US-6,092,522-B1	07/2000	Calvert et al.		
		Al1	US-6,102,035	08/2000	Asking et al.		
		AJ1	US-6,116,237-B1	09/2000	Schultz et al.		
$\mathcal{L}$	$\Box$		US-6,116,238-B1	09/2000	Jackson et al.		
		AL1	US-6,142,145	11/2000	Dagsland et al.		
1		AM1	US-US 2003/0094173-A1	05-22-2003	Burr et al.		

Examiner Signature	Date Considered	1 Jn antius
DG. 1201202.1		•

PTC/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
<u>ښ</u>	, , , , , , , , , , , , , , , , , , ,	•		Application Number	Divisional f 10/268,059	
11	NFORMATION	I DI	SCLOSURE	Filing Date	February 5, 2004	
S	TATEMENT I	BY /	APPLICANT	First Named Inventor	David Edwards	
		_ , ,		Art Unit	N/A	
	(Use as many sh	eets a	s necessary)	Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	000166.0109-US03	

[				FOREIG	GN PATENT	DOCUMENTS		
	C		Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
	Examiner Initials*		No.1	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T°
Ì	$\overline{}$		ΒA	EA-0 407 276-A2	01/1991	VALOIS Societe Anonyme		
1	-	1	<u> </u>			dite		
4	/		вв	EP-0 506 292-A1	09/1992	Rhone-Poulenc Rorer Limited		
A			BC	WO-WO 94/08552-A2	04/1994	Mecikalski et al.		
Ì	7	T	BD	WF-WO 00/64519-A1	11/2000	Haikarainen et al.		
ı	丈		1	WO-WO 01/07107	02/2001	Pharmaceutical Discovery		
1			0		]	Corporation		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\) Applicant's unique citation designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspic.gov">www.uspic.gov</a> or MPEP 901.04. \(^3\) Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the eppropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\) Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	and/or country where published.	ו
	S	Bisgaard, H. et al., Fine particle mass from the Diskus inhaler and Turbuhaler inhaler in children with asthma, European Respiratory Journal, 11: 1111-1115 (May 1998).	
	СВ	de Boer, A.H. et aql., "Inhalation characteristics and their effects on in vitro drug delivery from dry powder inhalers, Part 1. Inhalation characteristics, work on breathing and volunteers' preference in dependence of the inhaler resistance," International Journal of Pharmaceutics 130: 231-244 (1996).	
	CC	Dunbar, Craig A. et al., A Comparison of Dry Powder Inhaler Dose Delivery Characteristics Using a Power Criterion, PDA Journal of Pharmaceutical Science & Technology, 54(6): 4780484 (November/December 2000).	
	CD	Feddah, Majid R. et al., In-Vitro Characterisation of Metered Dose Inhaler Versus Dry Powder Inhaler Glucocorticoid Products: Influence of Inspiratory Flow Rates, J. Pham. Pharmaceut. Sci. (www.ualberta.ca/-csps) 3(3): 317-324 (2000).	
	CE	Koskela, T. et al., Efficacy of salbutamol via Easyhaler® unaffected by low inspiratory flow, Respiratory Medicine 94: 1229-1233 (December 2000).	
	CF	Nielsen, K.G. et al., Flow-dependent effect of formoterol dry-powder inhaled from the Aerolizer®, European Respiratory Journal, 10: 2105-2109 (September 1997).	
	CG	Richards, Robert and Saunders, Michael, Need for a comparative performance standard for dry powder inhalers, Thorax 48: 1186-1187 (November 1993).	
	СН	Ross, Danna L. and Schultz, Robert K., Effect of Inhalation Flow Rate on the Dosing Characteristics of Dry Powder Inhaler (DPI) and Metered Dose Inhaler (MDI) Products, Journal of Aerosol Medicine, 9: 215-226 (November 2, 1996).	
	0)	Smith, Karen J. et al., Influence of Flow Rate on Aerosole Particle Size Distributions from Pressurized and Breath-Actuated Inhalers, Journal of Aerosol Medicine, 11: 231-245 (November 4, 1998).	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

'Applicant's unique citation designation number-(optional): 'Applicant is to place a check mark here if English language Translation is attached.

		)	
Examiner Signature	Mand	Date Considered	75w05
			•